Fundz

Amicus Therapeutics

Princeton, New Jersey, United States · Biotechnology, Health Care, Therapeutics

We are leveraging our innovative technology platforms to develop treatments for human genetic diseases. Join a team committed to changing the lives of patients with rare metabolic diseases. Now hiring in multiple locations.

You have opened 5 full company profiles today. Create an account to keep reading them. Create an account

Key facts

Headquarters
Princeton, New Jersey, United States
Employees
500
Industries
Biotechnology, Health Care, Therapeutics
Website
amicusrx.com
LinkedIn
Company page

Recent activity at Amicus Therapeutics

  • : SEC 8-K (5.02): On April 27, 2026, the Company notified the Nasdaq Global Select Market of the completion of a Merger, resulting in a change in control as the Company became a wholly owned subsidiary of its Parent. In connection with this change, all outstanding shares of Company Common Stock were converted into the right to receive the Merger Consideration, effectively terminating the stockholders' rights. The trading of Company Common Stock will be suspended on Nasdaq on April 28, 2026, and the Company plans to file for deregistration. Key parties included the Company and its Parent, highlighting significant strategic implications following this transaction.
  • : SEC 8-K (8.01): On April 23, 2026, Amicus Therapeutics, Inc. announced that the Ministry of Economics and Finance in France granted clearance for its merger with BioMarin Pharmaceutical Inc. This French foreign direct investment clearance satisfies the final condition to the merger, allowing it to proceed as planned. The merger, first announced on December 19, 2025, is expected to close on April 27, 2026, making Amicus a wholly owned subsidiary of BioMarin. This clearance is crucial for the successful culmination of the merger and supports the strategic positioning of both companies in the biotech industry.
  • : SEC 8-K (7.01): Amicus Therapeutics, Inc. reported that as of December 31, 2025, it had approximately $294 million in cash and marketable securities and estimated total net product revenues of approximately $634 million for the year 2025. This information was provided to BioMarin Pharmaceutical Inc. in connection with the proposed acquisition of Amicus by BioMarin, with the aim to fund the acquisition via a private placement of senior notes. The preliminary unaudited financial data was included in a memorandum dated January 26, 2026, aligning with the acquisition process timeline and significant strategic implications for both companies involved.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Employee benefit plans

Amicus Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

About Amicus Therapeutics: questions and answers

What does Amicus Therapeutics do?

We are leveraging our innovative technology platforms to develop treatments for human genetic diseases. Join a team committed to changing the lives of patients with rare metabolic diseases. Now hiring in multiple locations.

Where is Amicus Therapeutics headquartered?

Amicus Therapeutics is headquartered in Princeton, New Jersey, United States.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics has about 500 employees.

What is the latest news on Amicus Therapeutics?

On Jan 26, 2026, SEC 8-K (5.02): On April 27, 2026, the Company notified the Nasdaq Global Select Market of the completion of a Merger, resulting in a change in control as the Company became a wholly owned subsidiary of its Parent. In connection with this change, all outstanding shares of Company Common Stock were c

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Amicus Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.